Is a complete DNLI research report available?

No complete published report is available for Denali Therapeutics Inc. (DNLI) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · USD

$23.9

-0.20 (-0.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first DNLI analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	3.8B
Net income (ttm)	-508M
EPS (ttm)	-$2.88
Shares out	158.7M
Volume	1,375,851
Beta	0.96
Price target	$34.3	+43.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -508M
EPS (ttm): -$2.88
Market cap: 3.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All DNLI indicators

Market & fundamental data

Available fields

192

Groups with data

Currency

USD

Showing 192 of 192 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001714899
Company name	Denali Therapeutics Inc.
Country	United States
Country code	US
Cusip	24823R105
Employees	507
Employees Change	64%
Employees Change Percent	14.45
Enterprise value	$2.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2017-12-08
Isin	US24823R1059
Last refreshed	2026-07-30
Market cap	$3.8B
Market cap category	Mid-Cap
Price	$23.85
Price currency	USD
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2836
Symbol	DNLI
Website	https://www.denalitherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-13.42%
EV Sales Forward	70.21x
FCF yield	-11.08%
P/B ratio	4.09x
PS Forward	95.81x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-406.4M
Net Income	$-508M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Profit Per Employee	$-1M
ROA	-26.95
Roa5y	-17.79
ROCE	-47.33
ROE	-49.59
Roe5y	-31.43
ROIC	-656.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	75.05%
Cagr3y	-5.18%
Cagr5y	-14.28%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$1.3B
Cash	$987.7M
Current Assets	$1B
Current Liabilities	$110.2M
Debt	$40M
Debt Equity	$0.04
Equity	$926.1M
Liabilities	$339.9M
Long Term Assets	$243.3M
Long Term Liabilities	$229.8M
Net Cash	$1B
Net Cash By Market Cap	$26.72
Net Cash Growth	0.92%
Net Debt Equity	$-1.09
Tangible Book Value	$890.1M
Tangible Book Value Per Share	$5.61
WACC	9.44

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.28
Net Working Capital	$-65.2M
Quick ratio	8.98
Working Capital	$912.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.87%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	74.98%
200-day SMA	19.75
3Y total return	-14.76%
50-day SMA	22.68
50-day SMA vs 200-day SMA	50over200
5Y total return	-53.71%
All Time High	93.94
All Time High Change	-74.61%
All Time High Date	2020-12-22
All Time Low	10.57
All Time Low Change	125.64%
All Time Low Date	2025-04-07
ATR	1.18
Beta	0.96
Beta1y	1.43
Beta2y	1.89
Ch YTD	44.46
High	24.39
High52	27.3
High52 Date	2026-07-09
High52ch	-12.64%
Low	23.61
Low52	12.58
Low52 Date	2025-09-22
Low52ch	89.59%
Ma50ch	5.15%
Premarket Change Percent	0.58
Premarket Price	$24.19
Premarket Volume	4,068
Price vs 200-day SMA	20.74%
RSI	50.74
RSI Monthly	54.78
RSI Weekly	59.3
Sharpe ratio	1.19x
Sortino ratio	1.91
Total Return	-3.87%
Tr YTD	44.46
Tr1m	-6.73%
Tr1w	0.89%
Tr3m	18.89%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	20
Analyst Count Top	13
Analyst Price Target Top	$34.9
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.57
Earnings Revenue Estimate	2,033,976x
Operating Income	$-547.1M
Price target	$34.31
Price Target Change	$43.86
Price Target Change Top	$46.33

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	144,219,329%
Float Percent	90.87%
Net Borrowing	-3,828,000
Shares Insiders	4.61%
Shares Institutions	100.27%
Shares Out	158,709,737
Shares Qo Q	6.37%
Shares Yo Y	3.87%
Short Float	11.12%
Short Ratio	7.65
Short Shares	10.1

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-516.8M
Adjusted OCF	-509,896,000
Average Volume	1,725,214.85x
Bv Per Share	5.84
CAPEX	$-6.9M
Ch1m	-6.73
Ch1w	0.89
Ch1y	74.98
Ch3m	18.89
Ch3y	-14.76
Ch5y	-53.71
Ch6m	14.44
Change	-0.83%
Change From Open	-1.45
Close	24.05
Days Gap	0.62
Depreciation Amortization	15,361,000
Dollar Volume	32,814,046.4
Earnings Date	2026-08-06
Earnings Time	amc
EBIT	$-547.1M
EBITDA	$-535.4M
EPS	$-2.88
F Score	1
FCF	$-419.2M
FCF EV Yield	-15.11x
FCF Per Share	$-2.64
Financing CF	412,022,000
Fiscal Year End	December
Founded	2,013
Income Tax	$102,000
Investing CF	330,993,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	20.64
Ma150ch	15.57%
Ma20	24.5
Ma20ch	-2.65%
Net CF	330,679,000
Next Earnings Date	2026-08-06
Open	24.2
Optionable	Yes
Position In Range	30.77
Post Close	23.85
Postmarket Change Percent	-0.46
Postmarket Price	$23.74
Ppne	117,266,000
Pre Close	24.05
Price Date	2026-07-29
Ptbv Ratio	4.25
Relative Volume	0.8x
Share Based Comp	97,560,000
Tr6m	14.44%
Us State	California
Volume	1,375,851

Denali Therapeutics Inc. (DNLI)

Coverage state: Market snapshot only — no published research

Generate the first DNLI analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · DNLI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DNLI indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on DNLI

Frequently asked questions